Pharma

Moderna reported sales of $3.1 billion, the comapny states this is a 53% decline from 2023. Read about the steps being taken to combat this decline in performance.

Dupixent has received FDA priority review for the treatment of bullous pemphigoid, a rare autoimmune skin disorder. If approved, Dupixent would become the first targeted therapy for BP, offering a safer and more effective treatment option.

Innovative GLP-1 and amylin receptor agonist shows up to 22% weight reduction in early-stage study.

Novartis' Phase III study of intrathecal onasemnogene abeparvovec for spinal muscular atrophy (SMA) successfully met its primary endpoint, showing significant motor function improvements.

GSK’s Nucala has been approved by China’s National Medical Products Administration for the treatment of adults with chronic rhinosinusitis with nasal polyps, offering a new therapeutic option for patients.

The BioFocus Editorial Team recap key developments from 2024 and highlight some of the most promising clinical trials and emerging therapies to keep an eye on.